{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:52:33Z","timestamp":1794361953925,"version":"4.9.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AG036778"],"award-info":[{"award-number":["K24AG036778"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL139671"],"award-info":[{"award-number":["R01HL139671"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AG058348"],"award-info":[{"award-number":["R21AG058348"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaccao.2021.07.010","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T05:32:17Z","timestamp":1634880737000},"page":"506-515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Electrophysiological Manifestations of Cardiac Amyloidosis"],"prefix":"10.1016","volume":"3","author":[{"given":"Jack","family":"Hartnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Sperry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyang R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oussama M.","family":"Wazni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"Donnellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2021.07.010_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13506129.2018.1549825","article-title":"Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"25","author":"Benson","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2021.07.010_bib2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib3","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib4","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.010_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.010_bib6","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2021.07.010_bib7","first-page":"113","article-title":"Left ventricular amyloid deposition inpatientswith heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jaccao.2021.07.010_bib8","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2021.07.010_bib9","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.010_bib10","first-page":"1935","article-title":"Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates","volume":"161","author":"Mendes Sousa","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib11","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","article-title":"Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways","volume":"21","author":"Sousa","year":"2001","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.jaccao.2021.07.010_bib12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0002-9440(10)64469-0","article-title":"Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro","volume":"161","author":"Sousa","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2011.04.133","article-title":"Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs","volume":"410","author":"Bourgault","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaccao.2021.07.010_bib14","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1007\/s12350-018-01477-y","article-title":"Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: a marker for neuropathy or cardiomyopathy in case of heart failure?","volume":"27","author":"Jonker","year":"2020","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.jcmg.2016.07.008","article-title":"Cardiac dysautonomia predicts long-term survival in hereditary transthyretin amyloidosis after liver transplantation","volume":"9","author":"Algalarrondo","year":"2016","journal-title":"J\u00a0Am Coll Cardiol Img"},{"key":"10.1016\/j.jaccao.2021.07.010_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/13506129.2020.1769059","article-title":"Cardiac sympathetic denervation in wild-type transthyretin amyloidosis","volume":"27","author":"Gimelli","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2021.07.010_bib17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.010_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib19","first-page":"1118","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis","volume":"6","author":"Donnellan","year":"2020","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jaccao.2021.07.010_bib20","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.010_bib21","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.010_bib22","first-page":"1473","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jaccao.2021.07.010_bib23","first-page":"727","article-title":"Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014","volume":"36","author":"Isath","year":"2020","journal-title":"J\u00a0Arrhythmia"},{"key":"10.1016\/j.jaccao.2021.07.010_bib24","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.jaccao.2021.07.010_bib25","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/thx.37.9.711","article-title":"Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine","volume":"37","author":"Griffiths","year":"1982","journal-title":"Thorax"},{"key":"10.1016\/j.jaccao.2021.07.010_bib26","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.010_bib27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2021.07.010_bib28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.010_bib29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/europace\/eux373","volume":"20","author":"Dan","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jaccao.2021.07.010_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ahj.2020.01.002","article-title":"Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter","volume":"222","author":"Loungani","year":"2020","journal-title":"Am Heart Jl"},{"key":"10.1016\/j.jaccao.2021.07.010_bib32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2021.07.010_bib33","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation a randomized clinical trial","volume":"312","author":"Reddy","year":"2014","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jaccao.2021.07.010_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccao.2021.07.010_bib36","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib37","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/pace.13992","article-title":"Catheter ablation of atrial fibrillation in cardiac amyloidosis","volume":"43","author":"Black-Maier","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"issue":"2","key":"10.1016\/j.jaccao.2021.07.010_bib38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jaccao.2021.07.010_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jaccao.2021.07.010_bib40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib41","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccao.2021.07.010_bib42","first-page":"1144","article-title":"Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"J\u00a0Am Coll Cardiol EP"},{"key":"10.1016\/j.jaccao.2021.07.010_bib43","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/jce.14180","article-title":"Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality","volume":"30","author":"Donnellan","year":"2019","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib44","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/pace.14023","article-title":"Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis","volume":"43","author":"Donnellan","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib45","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib46","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00380-015-0658-0","article-title":"Late gadolinium enhancement in cardiac amyloidosis: attributable both to interstitial amyloid deposition and subendocardial fibrosis caused by ischemia","volume":"31","author":"Hashimura","year":"2016","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jaccao.2021.07.010_bib47","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A\u00a0study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2021.07.010_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccao.2021.07.010_bib49","first-page":"694","article-title":"Survival following implantable cardioverter-defibrillator implantation in patients with amyloid cardiomyopathy","volume":"73","author":"Higgins","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2021.07.010_bib50","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/europace\/euaa094","article-title":"Outcomes in patients with cardiac amyloidosis and implantable cardioverter-defibrillator","volume":"22","author":"Kim","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.jaccao.2021.07.010_bib51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jce.12123","article-title":"Implantable cardioverter defibrillators in patients with cardiac amyloidosis","volume":"24","author":"Lin","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jaccao.2021.07.010_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccao.2021.07.010_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.010_bib54","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2021.07.010_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/13506129.2017.1374946","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.jaccao.2021.07.010_bib56","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO Study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2021.07.010_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087321001678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087321001678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:54:18Z","timestamp":1762973658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087321001678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2666087321001678"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2021.07.010","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Electrophysiological Manifestations of Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2021.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}